Latest Industry Insights

In this interview, Rolland Carlson, PhD, CEO of Immunexpress, discusses sepsis and the company’s FDA cleared SeptiCyte® RAPID test, as well as a take on the company’s differentiated value and outlook.

Technology Networks learns about serum epitope repertoire analysis and some of the applications it could benefit, including cancer diagnostics and COVID-19 studies.

Technology Networks spoke to Francisco Bizouarn, market development manager of the Digital Biology Group at Bio-Rad Laboratories, to find out how wastewater testing works and how it can anticipate a rise in cases of COVID-19 and the emergence of new variants.

In this interview, Lei Zhou, PhD, head of the Ocular Proteomics Platform at the Singapore Eye Research Institute, talks about the development of a novel diagnostic test to guide precision medicine to prevent dry eye in patients after laser eye surgery.

In this interview, Dr. Daniel Hornburg discusses how engineered nanoparticles could help to bridge the gap between proteomics and genomics and transform cancer diagnostics.

In this interview we speak to Sean Mackay, CEO of IsoPlexis, to discuss how single-cell functional proteomics have helped researchers understand the risk factors behind long COVID.

Emulate's chief scientific officer, Dr. Lorna Ewart, talks about inspiring a new generation of women in STEM.

This industry insight explores the findings from a comparative analysis of specific policies governing periodic updates to NBS panels in 30 European countries.

In this interview, Aiguo Zhang discusses some of the technologies that DiaCarta has developed within the liquid biopsy space and shares his thoughts on what the future may hold for the field.

Technology Networks had the pleasure of interviewing Dr. Oliver Rinner, CEO at Biognosys, to learn more about some of the recent developments in proteomics, and discuss what the future could hold for the field.